{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:13:48Z","timestamp":1789683228973,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.euroneuro.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T22:30:35Z","timestamp":1478903435000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials"],"prefix":"10.1016","volume":"27","author":[{"given":"Taina","family":"Mattila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Koeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitschak","family":"Storosum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eske","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubertus","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiaan","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7-8","key":"10.1016\/j.euroneuro.2016.10.004_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0278-5846(02)00242-7","article-title":"Insight in persons with schizophrenia: effects od switching from conventional neuroleptics to atypical antipsychotics","volume":"26","author":"Aguglia","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.10.004_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archpsyc.1994.03950100074007","article-title":"Awareness of illness in schizophrenia and schizoaffective and mood disorders","volume":"51","author":"Amador","year":"1994","journal-title":"Arch. Gen. Psych."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.10.004_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.eurpsy.2008.12.010","article-title":"Dissociating self-reported cognitive complaint from clinical insight in schizophrenia","volume":"24","author":"Bayard","year":"2009","journal-title":"Eur. Psychiatry"},{"issue":"1-3","key":"10.1016\/j.euroneuro.2016.10.004_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2015.01.003","article-title":"Is good insight associated with depression among patients with schizophrenia? Systematic review and meta-analysis","volume":"162","author":"Belvederi Murri","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.10.004_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.psychres.2014.03.022","article-title":"Effects of antipsychotic drugs on insight in schizophrenia","volume":"218","author":"Bianchini","year":"2014","journal-title":"Psych. Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.10.004_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00023210-200721020-00004","article-title":"Lack of insight in schizophrenia: impact on treatment adherence","volume":"21","author":"Buckley","year":"2007","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.10.004_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/13651501.2016.1141960","article-title":"Insight and recovery in schizophrenic patients","volume":"20","author":"Cannav\u00f2","year":"2016","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2016.10.004_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.10.004_bib9","first-page":"107","article-title":"Placebo response in clinical trials with schizophrenia patients","volume":"24","author":"Kinon","year":"2011","journal-title":"Curr. Opin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2016.10.004_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2013.10.013","article-title":"The nature and evolution of insight in schizophrenia: a multi-informant longitudinal study of first-episode versus chronic patients","volume":"151","author":"Koren","year":"2013","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.10.004_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.comppsych.2011.05.015","article-title":"Insight in schizophrenia and risk of suicide: a systematic update","volume":"53","author":"L\u00f3pez-Mor\u00ed\u00f1igo","year":"2012","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.10.004_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0920-9964(02)00316-X","article-title":"Insight in schizophrenia: a meta-analysis","volume":"61","author":"Minz","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.10.004_bib13","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.euroneuro.2015.02.012","article-title":"Differential effects of antipsychotic drugs on insight in first episode schizophrenia:data from the European First-Episode Schizophrenia Trial (EUFEST)","volume":"25","author":"Pijnenborg","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.10.004_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/S0033291797006296","article-title":"A comparative study of insights scales and their relationship to psychopathological and clinical variables","volume":"28","author":"Sanz","year":"1998","journal-title":"Psychol. Med."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16319630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16319630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T19:54:27Z","timestamp":1536263667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16319630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0924977X16319630"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.10.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}